The risks and incidence of K65R and L74V mutations and subsequent virologic responses

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 96-100

  Waters, Laura ^a   Nelson, Mark ^a   Mandalia, Sundhiya ^a   Bower, Mark ^a   Powles, Tom ^a   Gazzard, Brian ^a   Stebbing, Justin ^a,b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR;

ARTICLE; GENE MUTATION; GENE REPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; GENETIC PREDISPOSITION TO DISEASE; HIV; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VIRAL LOAD;

EID: 39349113994     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/523001     Document Type: Article

References (29)

1. Bartlett JA, Fath M, DeMasi R, et al. An updated meta-analysis of triple combination therapy in antiretroviral-naive HIV-infected adults [abstract 586]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
2. Camacho R, Theys K, Abecasis A, et al. Rise and fall of the RT K65R incidence in the Portugese resistance database [abstract 121]. Antivir Ther 2006; 11:S134.
3. Lanier ER, Givens N, Stone C, et al. Effect of concurrent zidovidine use on the resistance pathways selected by abvacavir-containing regimens. HIV Med 2004; 4:394-9.
4. Underwood M, St Clair M, Ross L, et al. Cross-resistance of clinical samples with K65R, L74V, and M184V mutations [abstract 714]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
5. Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-46.
6. McColl DJ, Bae AS, Waters JM, Margot NA, Borrota-Esoda K, Miller MD. Prior abacavir (ABC) or didanosine (ddI) therapy with development of L74V is a risk factor for virological non-response and development of K65R in patients taking tenofovir DF (TDF). Int Cong Drug Therapy HIV 2004; 7:113.
7. Irlbeck D, Rouse E, Castillo S, et al. Treatment emergent mutations for previously naïve HIV-infected adults failing ZDV+3TC+EFV and ABC+3TC+EFV (CNA30024) [abstract M-112, poster 661]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
8. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004; 18:651-5.
9. Parikh U, Koontz D, Sluis-Cremer N, et al. K65R: a multinucleoside resistance mutation of increasing prevalence exhibits bi-directional phenotypic antagonism with TAM [abstract 54]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
10. Winston A, Mandalia S, Pillay D, et al. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovirnaive patients. AIDS 2002; 16:2087-9.
11. Winston A, Pozniak A, Mandalia S, et al. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase. AIDS 2004; 18:949-57.
12. Maitland D, Moyle G, Hand J, et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 2005; 19:1183-8.
13. Leon A, Martinez E, Mallolas J, et al. Early virological failure in treatment-naïve HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005; 19:213-5.
14. Podzamczer D, Ferrer E, Gatell JM, et al. Early virologic failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther 2005; 10:171-7.
15. Farthing C, Khanlou H, Yeh V, et al. Early virological failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients [abstract 43]. In: Programs and abstracts of the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment (Paris). Paris: International AIDS Society, 2003.
16. Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus Study [abstract 52]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
17. Jemsek J, Hutcherson P, Harper E, et al. Poor virologic responses and early emergence of resistance in treatment naive, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF [abstract 51]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retrovirology and Human Health, 2004.
18. Gallant JE, Rodriguez AE, Weinberg W, et al. Early virological non-response to tenofovir, abacavir and lamivudine in HIV-infected antiretroviral-naïve subjects. J Infect Dis 2005; 192:1921-30.
19. Moyle G, Nelson M, Higgs C, et al. A randomised open label comparative study of combivir + efavirenz (2 class triple therapy) versus trizivir plus tenofovor (singel class quadruple therpy) in initial therapy for HIV-1 infection [abstract H1131]. In: Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy (Washington, DC). Washington, DC: American Society for Microbiology, 2004.
20. Latham V, Stebbing J, Mandalia S, et al. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and decreased cholesterol. J Antimicrob Chemother 2005; 56:186-9.
21. Rodriguez AE, Hill-Zabala CE, Sloan LA, et al. Quadruple nucleoside/tide regimen of trizivir (TZV) + tenofovir (TDF) is effective following early virologic failure on an initial regimen containing a thymidine analogue + lamivudine in combination with a protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) (ESS30005, ZIP) [abstract WePE6.3c03]. In: Program and abstracts of the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment (Rio de Janeiro). Stockholm: International AIDS Society, 2004.
22. Mutuluuza CK, Walker S, Kaleebu P. Short-term virologic response (24 weeks) to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial [abstract 22]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2005.
23. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-61.
24. Nassar N, Armas L, Smillie J, et al. An observational cohort comparison of zidovudine-lamivudine-efavirenz to zidovudine-lamivudine-abacavir in antiretroviral-naive individuals [abstract 554]. In: Program and abstracts of the 2nd International AIDS Society Conference on HIV (Paris). Stockholm: International AIDS Society, 2003.
25. Johnson M, De Wit S, Gazzard B, et al. Induction therapy with Trizivir (zidovudine/lamivudine/abacavir) [TZV] plus efavirenz [EFV]: TIME Study (AZL30004) results at 24 weeks [abstract F1/4]. In: Program and abstracts of the 9th European AIDS Conference (Warsaw, Poland). 2003.
26. Markowitz M, Hill-Zabala C, Lang J, et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48 week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral- naïve HIV-1 infected patients. J Acquir Immune Defic Syndr 2005; 39:257-64.
27. Margot NA, Lu B, Cheng A, Miller MD; Study 903 Team. Resistance development of 144 weeks in treatment-naïve patients receiving tenofovir disproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 2006; 7:442-50.
28. Tung MY, Mandalia S, Bower M, Gazzard B, Nelson M. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily. HIV Med 2005; 6:151-4.
29. Blick G, Greiger-Zanlungo P, Dupree D, Assaro J, Garton T, Arzu Z. Tenofovir DF can be safely used in combination with didanosine-EC 250mg: effects on lymphocytes, CD4, viral load and GFR [abstract TuPe2.3C22]. In: Program and abstracts of the International AIDS Society Conference on HIV Pathogenesis and Treatment. Stockholm: International AIDS Society, 2005.